Tradewinds Capital Management’s Purple Biotech PPBT Stock Holding History

Tradewinds Capital Management’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$7	–	743
2025 Q4	$7	Sell	1 -9	-90%	-$65	﹤0.01%	684
2025 Q3	$58	Buy	+10	New	+$179	﹤0.01%	663
2021 Q2	–	Sell	-3	Closed	-$2K	–	806
2021 Q1	$2K	Buy	+3	New	+$2.8K	﹤0.01%	641

Other funds holding PPBT

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Tradewinds Capital Management's PPBT Position: Q1 2026 in Review

Tradewinds Capital Management sold out of Purple Biotech (PPBT) in Q1 2026, closing a stake of 1 share — an estimated $7 sold.

Tradewinds Capital Management first reported a position in PPBT in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2021. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.

Tradewinds Capital Management reported no remaining Purple Biotech position as of Q1 2026 after selling out during the quarter.
Tradewinds Capital Management sold 1 Purple Biotech share in Q1 2026, an estimated $7.
Tradewinds Capital Management first reported a position in Purple Biotech in Q1 2021 and held it in 3 quarters.
Tradewinds Capital Management's Purple Biotech position peaked at $2K in Q1 2021.
15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.

Based on Tradewinds Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.